Cholesterol metabolism in cardiac sarcoidosis. (May 2016)
- Record Type:
- Journal Article
- Title:
- Cholesterol metabolism in cardiac sarcoidosis. (May 2016)
- Main Title:
- Cholesterol metabolism in cardiac sarcoidosis
- Authors:
- Simonen, Piia
Lehtonen, Jukka
Gylling, Helena
Kupari, Markku - Abstract:
- Abstract: Background and aims: Patients with cardiac sarcoidosis (CS) suffer from myocardial inflammation, but atherosclerosis is not infrequent in these patients. However, the classical atherosclerotic risk factors, such as perturbed serum lipids and whole-body cholesterol metabolism, remain unravelled in CS. Methods: We assessed serum non-cholesterol sterols, biomarkers of whole-body cholesterol synthesis and cholesterol absorption efficiency, with gas-liquid chromatography in 39 patients with histologically verified CS and in an age-adjusted random population sample (n = 124). Results: CS was inactive or responding to treatment in all patients. Concentrations of serum, LDL, and HDL cholesterol and serum triglycerides were similar in CS patients and in control subjects. Cholesterol absorption markers were higher in CS patients than in controls (eg serum campesterol to cholesterol ratio in CS 246 ± 18 vs in controls 190 ± 8 10 2 x μmol/mmol of cholesterol, p = 0.001). Cholesterol synthesis markers were lower in CS patients than in controls (eg serum lathosterol to cholesterol ratio in CS 102 ± 8 vs in controls 195 ± 5 10 2 x μmol/mmol of cholesterol, p = 0.000). In CS patients, cholesterol absorption markers significantly correlated with plasma prohormone brain natriuretic peptide (proBNP), a marker of hemodynamic load. Conclusion: High cholesterol absorption efficiency, which is suggested to be atherogenic, characterized the metabolic profile of cholesterol in CS patients.Abstract: Background and aims: Patients with cardiac sarcoidosis (CS) suffer from myocardial inflammation, but atherosclerosis is not infrequent in these patients. However, the classical atherosclerotic risk factors, such as perturbed serum lipids and whole-body cholesterol metabolism, remain unravelled in CS. Methods: We assessed serum non-cholesterol sterols, biomarkers of whole-body cholesterol synthesis and cholesterol absorption efficiency, with gas-liquid chromatography in 39 patients with histologically verified CS and in an age-adjusted random population sample (n = 124). Results: CS was inactive or responding to treatment in all patients. Concentrations of serum, LDL, and HDL cholesterol and serum triglycerides were similar in CS patients and in control subjects. Cholesterol absorption markers were higher in CS patients than in controls (eg serum campesterol to cholesterol ratio in CS 246 ± 18 vs in controls 190 ± 8 10 2 x μmol/mmol of cholesterol, p = 0.001). Cholesterol synthesis markers were lower in CS patients than in controls (eg serum lathosterol to cholesterol ratio in CS 102 ± 8 vs in controls 195 ± 5 10 2 x μmol/mmol of cholesterol, p = 0.000). In CS patients, cholesterol absorption markers significantly correlated with plasma prohormone brain natriuretic peptide (proBNP), a marker of hemodynamic load. Conclusion: High cholesterol absorption efficiency, which is suggested to be atherogenic, characterized the metabolic profile of cholesterol in CS patients. The association between cholesterol absorption efficiency and plasma proBNP concentration, which suggests a link between inflammation, cholesterol homeostasis, and hemodynamic load, warrants further studies in order to confirm this finding and to reveal the underlying mechanisms. Highlights: Atherosclerotic risk factors, ie perturbed serum lipids and whole-body cholesterol metabolism, remain unknown in cardiac sarcoidosis (CS). Cholesterol metabolism was evaluated in 39 patients with histologically verified CS and in an age- adjusted random population sample (n = 124). Cholesterol absorption was upregulated and cholesterol synthesis downregulated in CS. Serum lipids were similar between groups. High cholesterol absorption efficiency, suggested to be atherogenic, characterised the metabolic profile of cholesterol in CS. … (more)
- Is Part Of:
- Atherosclerosis. Volume 248(2016)
- Journal:
- Atherosclerosis
- Issue:
- Volume 248(2016)
- Issue Display:
- Volume 248, Issue 2016 (2016)
- Year:
- 2016
- Volume:
- 248
- Issue:
- 2016
- Issue Sort Value:
- 2016-0248-2016-0000
- Page Start:
- 210
- Page End:
- 215
- Publication Date:
- 2016-05
- Subjects:
- Atherosclerosis -- Campesterol -- Cholesterol absorption -- Cholesterol synthesis -- Inflammation -- Lathosterol -- Myocardial disease
Arteriosclerosis -- Periodicals
Electronic journals
616.136 - Journal URLs:
- http://www.sciencedirect.com/science/journal/00219150 ↗
http://www.clinicalkey.com/dura/browse/journalIssue/00219150 ↗
http://www.elsevier.com/journals ↗ - DOI:
- 10.1016/j.atherosclerosis.2016.03.018 ↗
- Languages:
- English
- ISSNs:
- 0021-9150
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 1765.874000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 7467.xml